Detalhe da pesquisa
1.
Three monthly doses of palivizumab are not adequate for 5-month protection: a population pharmacokinetic analysis.
Pulm Pharmacol Ther
; 26(6): 666-71, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23523663
2.
Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids.
Clin Pharmacokinet
; 61(4): 577-587, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34878624
3.
Validation of a quantitative systems pharmacology model of calcium homeostasis using elagolix Phase 3 clinical trial data in women with endometriosis.
Clin Transl Sci
; 14(4): 1611-1619, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33963686
4.
Integrating real-world data and modeling to project changes in femoral neck bone mineral density and fracture risk in premenopausal women.
Clin Transl Sci
; 14(4): 1452-1463, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33650259
5.
Effect of Elagolix Exposure on Clinical Efficacy End Points in Phase III Trials in Women With Endometriosis-Associated Pain: An Application of Markov Model.
CPT Pharmacometrics Syst Pharmacol
; 9(8): 466-475, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32621325
6.
Exposure-Safety Analyses Identify Predictors of Change in Bone Mineral Density and Support Elagolix Labeling for Endometriosis-Associated Pain.
CPT Pharmacometrics Syst Pharmacol
; 9(11): 639-648, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32945631
7.
Exposure-Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit-Risk Assessment in Rheumatoid Arthritis.
Clin Pharmacol Ther
; 107(4): 994-1003, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31610021
8.
Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis.
Clin Pharmacokinet
; 59(3): 297-309, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31749075
9.
Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I-III Clinical Trials.
Clin Pharmacokinet
; 58(8): 1045-1058, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30945116
10.
Population Pharmacokinetics of Elagolix in Healthy Women and Women with Endometriosis.
Clin Pharmacokinet
; 57(10): 1295-1306, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29476499
11.
Population Pharmacokinetics and Immunogenicity of Adalimumab in Adult Patients with Moderate-to-Severe Hidradenitis Suppurativa.
Clin Pharmacokinet
; 56(9): 1091-1102, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28066879
12.
Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
Clin Ther
; 25(6): 1700-21, 2003 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-12860493
13.
Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia.
Cancer Chemother Pharmacol
; 74(3): 593-602, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25053389
14.
Exposure-clinical response analysis of paricalcitol in patients with chronic kidney disease (stage 5) on hemodialysis or peritoneal dialysis.
J Clin Pharmacol
; 52(8): 1162-73, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-21940716